Kuros Biosciences Reports Financial Results for 2016
(WorldNews Switzerland)

o Merger successfully completed: Cytos Biotechnology and Kuros Biosurgery Holding combined their businesses to create Kuros Biosciences, a future leader in tissue repair and regeneration o Transition to commercial-stage accelerated: Acquisition of Xpand in January 2017 results in orthobiologics company with commercial-ready products in the European Union (EU) and in the United States of America (US) o Shift towards commercialization realized: Kuros names commercialization veteran Dr. IvanCohen-Tanuginew CEO; MagnetOs Granules is approved in the EU and the US and Neuroseal (KUR-023) is awaiting CE mark certification. o Financials influenced by IFRS3 accounting: For accounting purposes, the...